Circulating rare cells (CRCs) are benign or malignant minuscule events in the peripheral blood or other bodily fluids. The detection and quantification of certain CRC types is an invaluable or proposed candidate biomarker for diagnosis, prognosis and prediction of various pathological conditions. The list of CRC types and biomarker applicability thereof continues to expand along with improvements in cell selection technology. Past findings may suggest commonness of healthy donor peripheral blood circulating mature erythroblasts. This work suggests the occurrence of morphologically distinct bone marrow native circulating early erythroid precursors that we intend to add to the list of CRCs.
Introduction
Various circulating rare cell (CRC) types may exist amongst the main cellular constituents of the blood and in other bodily fluids depending on age and health status. Rarity may account for concentrations lower than 1,000 cells per mL (1) (2) (3) (4) . The emergence and/or elevation in frequency of certain CRC types may represent benign or more severe pathological conditions such as autoimmunity, immune deficiency and hematologic, cardio-vascular, cancer and other malignancies (2, (5) (6) (7) (8) (9) . Therefore, the detection and quantification of certain CRCs has been used or has potential to be used as diagnostic, prognostic and predictive biomarker (2, (10) (11) (12) (13) (14) and in non-invasive prenatal diagnosis (15, 16) . Clinically relevant CRC types may include stem and progenitor cells purposed for tissue regeneration and wound healing (17, 18) . Other types may include aberrant as well as non-aberrant cells of endothelial, epithelial or mesenchymal origin (2, (5) (6) (7) . Also, cells native to the bone marrow, such erythroblasts and megakaryocytes have been identified (3, 19, 20) .
CRCs that are foreign to peripheral blood are deficient of the common leukocyte antigen CD45 and best enriched by depletion of leukocytes also known as the negative selection principle. Improvement in such technologies enables "mining" for new CRC types in presumption of clinical translation as candidate biomarkers. Left over nucleated cellular fractions of healthy donor blood samples after microchip facilitated red blood cell and CD45 positive cell depletion revealed abundance of bone marrow native erythroblasts, suggesting rarity yet commonness of such erythroid related cell types (3). To date, erythroblasts are routinely identified by blood analysers requiring concentrations above 1×10 4 cells per mL, which then is commonly associated with severe pathological conditions such as cancer, ischemia and haematological disorders (8) .
In this work, we isolated erythroblasts from healthy donors based on the negative selection principle. Our findings allude to the detection of erythroblast-like cells at different stages of maturation. Future work intends to investigate the correlation of frequency and stage of early erythroblasts with health status, as such proving usefulness as prognostic as well as early stage diagnostic biomarker in particular in oncology.
Methods

Blood collection and processing
Blood samples were obtained from PB collected from healthy volunteer subjects using standard 21G' butterfly needle set. PB was taken by venous puncture collecting 8 mL in green-top BD Vacutainer blood collection tubes containing sodium heparin. The blood sample was processed immediately after phlebotomy or at latest 3 hours after. The study protocol was undertaken as approved by the institutional review board/independent ethics committee of Mahidol University. Informed consent was sought from blood donors at each time.
Red blood cell lysis
Standard chemical lysis buffer treatment was applied to remove red blood cells (RBC) (154 mM NH 4 Cl, 10 mM NaHCO 3 , 2 mM EDTA) from 5 mL whole blood adjusting the blood sample to lysis buffer ratio to 1:25 for PB. The cell suspension was incubated at RT for max. Five min and subsequently centrifuged at 300×g for another 10 minutes. The cell pellet was resuspended in 10 mL PBS, supplemented with 0.5% bovine serum albumin and washed by centrifugation at 200×g for 10 minutes. The final cell pellet of nucleated cells with contaminations of platelets and RBCs was resuspended in 1 mL Gibco ® Advanced RPMI 1640 and kept at 4 ℃. The cell numbers of nucleated cells were determined by hemocytometer (Neubauer) and subjected to experimentation within 1 hour.
Isolation and detection assay
We isolated and detected peripheral blood rare cells from healthy donor PB after RBC lysis by negative selection based on magnetic bead cell separation technology and by fluorescence microscopy. The magnetic bead assay followed descriptions of our previously described dynamic magnetic labeling (DML) procedure (21) . In brief, nucleated cell counts were adjusted to maximal 3×10 7 nucleated cells after RBC lysis from initially 3.5 to 8 mL whole blood. The enrichment procedure followed 2 cycles of DML enrichment using a prototype semi-automated magnetic labelling system (SanoLibio GmbH, Deutschland) and magnetic beads reactive against CD45 (SanoLibio GmbH, Deutschland). After each depletion cycle, uncaptured cell material was pelleted at 300×g for 5 minutes and at room temperature. Subsequent to enrichment, the untouched life cell suspension was stored in 1 mL Gibco ® Advanced RPMI 1640 at 4 ℃ for further use not longer than 1 hour. For microscopic analysis untouched and enriched life cell suspensions were adjusted to 30 µL and incubated in Gibco ® Advanced RPMI 1640 with anti-CD45PE
(ebioscience), anti-CD71FITC (ebioscience) and antiGPAPerCP-C5.5 (ebioscience) each using 1 µL undiluted dye solution in the cold and dark for 20 minutes. Nucleus staining followed using 0.5 µL Hoechst 33342 DNA staining (ThermoFischer). The suspension was washed in 1.5 mL PBS and subsequent centrifugation, 300×g 5 min at 4 ℃. The pellet was resuspended in 70 µL DMEM Media not containing phenol red (ThermoFischer) and loaded into one well of a specialized 96-well plate suitable for high resolution image recording at 40× magnification using the Operetta system (PerkinElmar) recording a bright field channel, and channels for UV, green, yellow and red fluorescence emission. Columbus analysis software served as screening and image analysis tool. Staining positive cells were identified by a cell-like round formation identifiable by morphology, positive high intensity Hoechst staining and positive FITC fluorescence in the absence of the typical ring formation as consequence of positive CD45PE staining throughout the emission light spectrum from 520 till 650 nm.
Results
We investigated the occurrence of erythroid precursors in peripheral blood that are commonly associated with pathological findings and have been rarely reported for its presence in healthy individuals. Blood donors appeared in healthy condition with respect to feeling, which was further supported by additional hematology data of some of the donors ( Table 1) . We used our previously reported panCD45neg cell enrichment assay based on the DML method for enhanced enrichment of rare cells in the PB by negative selection (21) . The pan-CD45neg cell assay allowed an approximate 100× sample volume reduction from a mean blood volume of 4.7 mL (range, 3.5-8 mL). The lower final volume facilitated analysis by automated microscopy image recording in one microplate well per sample, which was convenient for experimental practice and allowed relative short image recording time. Removal of RBCs and high depletion of leukocytes was necessary to avoid cell crowding at the well bottom otherwise rendering image analysis impossible. The negative cell selection principle is independent of marker expression. Therefore, the DML method allows the "None" counted 0, and "a" is obsolete in case "b" is suggestive for the second time blood draw of the same donor; "b" means repeated testing of the same donor with a time gap of at least 7 months. *, donors tested with additional hematology data indicating anaemia and inflammation ( Table 1) .
detection of CD45 negative erythroblasts at any stage of maturation apart from the CD45 positive pro-erythroblast. RBC line specific characterization of the carryover rare cell populations was done by immuno-phenotyping marking CD71 and GPA as positive events. In general, erythroid precursors can be characterized by immunophenotyping using a set of cell surface markers that include the transferrin receptor antigen CD71, GPA, Kell blood group protein, integrin associated protein CD47, and the glycoprotein antigen CD44. High expression of CD71 and GPA are unique to cells related to the nucleated red blood cell line (22) . Previous findings would allow the expectation to detect CRCs of the erythroid lineage in the carryover fraction after depletion of WBCs (3). However, detailed morphological distinctions have not been reported so far and positive cell exhibitions included rather small cells not exceeding 10 µm in diameter. Our results show intra and inter donor variation of CD71/GPA positive cells related to the morphological appearance under bright field microscope and the cell and nucleus diameter (Figure 1) .
The assumption seems likely of distinct stages of cell maturation that may include basophilic erythroblasts (BasoE), polychromatophilic, erythroblasts (PolyE) and orthochromatic erythroblasts (OrthoE). Fluorescence staining protocols have been applied to erythroblast staging using cell and nuclear size as well as fluorescence signal intensities characteristics (23, 24) . The expression of the transferrin receptor CD71 is generally expected to decrease and nucleus intensity to increase with progress of maturation, due to progressive nuclear condensation. However, the interpretation is not without pitfalls. The CD71 correlation with maturation in particular for stages between BasoE and OthoE are not stringently reproducible (23) . Also, in case of PB circulating erythroblasts, marker expression, mode of differentiation and cell viability may be altered over time as a result of dwelling in an environment other than the bone marrow. Furthermore, the small number of in particular larger cells does not provide statistical significance. In view of the uncertainties, classical or detailed staging of PB circulating erythroblasts may be difficult. Therefore, we group positive events coarsely into immature, less matured and matured erythroblasts according to bright field appearance, cell and nuclear size (Figure 1) . Thus, immature erythroblasts would include cells with cell and nucleus size larger than 13.5 and 6.5 µm in diameter, respectively as shown in Figure 1 , rows 4 to 6. Less mature EBs would be larger in either or both cell or nucleus size, thus ranging from 10 till 13.5 µm and 6.5 till 8 µm, respectively and illustrated in Figure 1 rows 2 and 3 . The smallest cells are expected to have reached a final stage of maturation with cell and nucleus size below 10 and 6.5 µm, respectively. The results suggest the idea of EB maturation stage profiles and show that rarity increases with cell size, thus cell immaturity ( Table 2 ). Inflammation as indicated by the C-reactive protein concentration was not correlated with appearance of in particular immature erythroblasts. Donor 11 stands out with a high concentration of in particular mature erythroblasts that may be correlated with a stable and asymptomatic condition of slight anemia and/or an underlying condition of thrombocytosis (7.8×10 5 platelets per uL). The presence of in particular less mature and immature EBs in the circulation is commonly expected to be disease-and disease stage related (8, 20) . Recent work has revealed nucleated red blood cells to possess functionalities similar to innate as well as adaptive immune cells in trout (25) and chicken (26) , as such being players in inflammation and infection (27) .
Conclusions
In view of the general donor healthiness on grounds of feeling and hematology data, our findings of immature erythroblasts may represent a benign baseline concentration. We may hypothesize that the assessment of the EB profile as proposed in this work could be a useful biomarker for health status identification in general, early stage disease detection, such as in situ tumor growth or cancer therapy monitoring and response. the Mahidol University Postdoctoral program and in parts by the Thailand Center of Excellence in Physics.
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